With stromal tumor infiltrating lymphocytes (TILs) being a prognostic biomarker in non-luminal breast cancer, researchers have evaluated their clinical relevance in luminal (hormone receptor-positive and HER2-negative) early breast cancer. This evidence concerns the gene ERBB2 and breast cancer.